Ayyildiz H, Salmaslioglu A, Tunaci A, Erturk S
Sisli Etfal Hastan Tıp Bul. 2023; 57(2):153-162.
PMID: 37899806
PMC: 10600631.
DOI: 10.14744/SEMB.2023.77910.
Zhou X, Fan X, Chatterjee A, Yousuf A, Antic T, Oto A
Phys Eng Sci Med. 2023; 46(3):1215-1226.
PMID: 37432557
DOI: 10.1007/s13246-023-01289-6.
Bai J, Qiu S, Zhang G
Signal Transduct Target Ther. 2023; 8(1):89.
PMID: 36849435
PMC: 9971190.
DOI: 10.1038/s41392-023-01366-y.
Zhou X, Fan X, Chatterjee A, Yousuf A, Antic T, Oto A
Res Sq. 2023; .
PMID: 36798227
PMC: 9934750.
DOI: 10.21203/rs.3.rs-2539644/v1.
Doleschel D, Hoff S, Koletnik S, Rix A, Zopf D, Kiessling F
J Exp Clin Cancer Res. 2021; 40(1):288.
PMID: 34517894
PMC: 8436536.
DOI: 10.1186/s13046-021-02043-0.
A Novel Statistical Optimization Algorithm for Estimating Perfusion Curves in Susceptibility Contrast-Enhanced MRI.
Hu Z, Li F, Shui J, Tang Y, Lin Q
Front Neurosci. 2021; 15:713893.
PMID: 34512247
PMC: 8427443.
DOI: 10.3389/fnins.2021.713893.
Multi-parametric MRI (mpMRI) for treatment response assessment of radiation therapy.
Wang C, Padgett K, Su M, Mellon E, Maziero D, Chang Z
Med Phys. 2021; 49(4):2794-2819.
PMID: 34374098
PMC: 9769892.
DOI: 10.1002/mp.15130.
Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
Fiegle E, Doleschel D, Koletnik S, Rix A, Weiskirchen R, Borkham-Kamphorst E
Neoplasia. 2019; 21(9):932-944.
PMID: 31412307
PMC: 6700499.
DOI: 10.1016/j.neo.2019.07.006.
Patient-specific pharmacokinetic parameter estimation on dynamic contrast-enhanced MRI of prostate: Preliminary evaluation of a novel AIF-free estimation method.
Ginsburg S, Taimen P, Merisaari H, Vainio P, Bostrom P, Aronen H
J Magn Reson Imaging. 2016; 44(6):1405-1414.
PMID: 27285161
PMC: 5559229.
DOI: 10.1002/jmri.25330.
Dynamic Contrast-Enhanced MR Imaging in Head and Neck Cancer: Techniques and Clinical Applications.
Gaddikeri S, Gaddikeri R, Tailor T, Anzai Y
AJNR Am J Neuroradiol. 2015; 37(4):588-95.
PMID: 26427839
PMC: 7960151.
DOI: 10.3174/ajnr.A4458.
GPU-accelerated compartmental modeling analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab.
Hsu Y, Huang Z, Ferl G, Ng C
PLoS One. 2015; 10(3):e0118421.
PMID: 25786263
PMC: 4364976.
DOI: 10.1371/journal.pone.0118421.
Unsupervised deconvolution of dynamic imaging reveals intratumor vascular heterogeneity and repopulation dynamics.
Chen L, Choyke P, Wang N, Clarke R, Bhujwalla Z, Hillman E
PLoS One. 2014; 9(11):e112143.
PMID: 25379705
PMC: 4224420.
DOI: 10.1371/journal.pone.0112143.
Review of treatment assessment using DCE-MRI in breast cancer radiation therapy.
Wang C, Yin F, Horton J, Chang Z
World J Methodol. 2014; 4(2):46-58.
PMID: 25332905
PMC: 4202481.
DOI: 10.5662/wjm.v4.i2.46.
DCE@urLAB: a dynamic contrast-enhanced MRI pharmacokinetic analysis tool for preclinical data.
Ortuno J, Ledesma-Carbayo M, Simoes R, Candiota A, Arus C, Santos A
BMC Bioinformatics. 2013; 14:316.
PMID: 24180558
PMC: 4228420.
DOI: 10.1186/1471-2105-14-316.
Role of quantitative pharmacokinetic parameter (transfer constant: K(trans)) in the characterization of breast lesions on MRI.
Amarnath J, Sangeeta T, Mehta S
Indian J Radiol Imaging. 2013; 23(1):19-25.
PMID: 23986614
PMC: 3737611.
DOI: 10.4103/0971-3026.113614.
Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation.
Barnes S, Whisenant J, Loveless M, Yankeelov T
Pharmaceutics. 2012; 4(3):442-78.
PMID: 23105959
PMC: 3480221.
DOI: 10.3390/pharmaceutics4030442.
Tissue-specific compartmental analysis for dynamic contrast-enhanced MR imaging of complex tumors.
Chen L, Choyke P, Chan T, Chi C, Wang G, Wang Y
IEEE Trans Med Imaging. 2011; 30(12):2044-58.
PMID: 21708498
PMC: 6309689.
DOI: 10.1109/TMI.2011.2160276.
A quantitative comparison of the influence of individual versus population-derived vascular input functions on dynamic contrast enhanced-MRI in small animals.
Loveless M, Halliday J, Liess C, Xu L, Dortch R, Whisenant J
Magn Reson Med. 2011; 67(1):226-36.
PMID: 21688316
PMC: 3179805.
DOI: 10.1002/mrm.22988.
Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases.
Shukla-Dave A, Lee N, Jansen J, Thaler H, Stambuk H, Fury M
Int J Radiat Oncol Biol Phys. 2011; 82(5):1837-44.
PMID: 21601373
PMC: 3177034.
DOI: 10.1016/j.ijrobp.2011.03.006.
Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.
Franiel T, Hamm B, Hricak H
Eur Radiol. 2010; 21(3):616-26.
PMID: 21184082
DOI: 10.1007/s00330-010-2037-7.